Omae Kiyotsugu, Ogawa Tetsuya, Yoshikawa Masao, Nitta Kosaku
Department of Internal Medicine, Yoshikawa Hospital, Tokyo, Japan.
Heart Vessels. 2010 Mar;25(2):163-9. doi: 10.1007/s00380-009-1183-9. Epub 2010 Mar 26.
Suppression of left ventricular (LV) remodeling secondary to heart failure seems critical to improve the prognosis of hemodialysis (HD) patients. This is a retrospective study on the relationship of an antiallergic drug and antihistamines with LV hypertrophy. A total of 149 patients (88 males and 61 females) were entered in the study. Mean age was 66.7 years and mean duration of dialysis 14.4 years. Twenty-three patients received oral treatment with an antiallergic drug or second-generation antihistamines, 3 with the antiallergic drug and 20 with antihistamines. The multivariate analysis using LV mass index (LVMI) as the objective variable extracted the following independent factors: male sex, erythropoietin (EPO)/w, uric acid (UA), total cholesterol, antihistamines, antiallergic drug, and calcium channel blocker (CCB), with a standard regression coefficient of 0.187, 0.196, 0.212, -0.262, -0.215, -0.149 and -0.173, respectively. This study suggests a suppressive role of second-generation antihistamines on LV remodeling. Male sex, high-dose EPO/w, and elevated UA were considered as aggravating factors, and CCB as a suppressive factor.
抑制继发于心力衰竭的左心室（LV）重塑似乎对改善血液透析（HD）患者的预后至关重要。这是一项关于一种抗过敏药物和抗组胺药与左心室肥厚关系的回顾性研究。共有149例患者（88例男性和61例女性）纳入研究。平均年龄为66.7岁，平均透析时间为14.4年。23例患者接受了抗过敏药物或第二代抗组胺药的口服治疗，其中3例接受抗过敏药物治疗，20例接受抗组胺药治疗。以左心室质量指数（LVMI）为目标变量的多变量分析提取了以下独立因素：男性、促红细胞生成素（EPO）/体重、尿酸（UA）、总胆固醇、抗组胺药、抗过敏药物和钙通道阻滞剂（CCB），标准回归系数分别为0.187、0.196、0.212、-0.262、-0.215、-0.149和-0.173。本研究提示第二代抗组胺药对左心室重塑有抑制作用。男性、高剂量EPO/体重和UA升高被认为是加重因素，CCB是抑制因素。
